Cargando…
Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)
AIMS: The COLchicine Cardiovascular Outcomes Trial (COLCOT) demonstrated the benefits of targeting inflammation after myocardial infarction (MI). We aimed to determine whether time-to-treatment initiation (TTI) influences the beneficial impact of colchicine. METHODS AND RESULTS: In COLCOT, patients...
Autores principales: | Bouabdallaoui, Nadia, Tardif, Jean-Claude, Waters, David D, Pinto, Fausto J, Maggioni, Aldo P, Diaz, Rafael, Berry, Colin, Koenig, Wolfgang, Lopez-Sendon, Jose, Gamra, Habib, Kiwan, Ghassan S, Blondeau, Lucie, Orfanos, Andreas, Ibrahim, Reda, Grégoire, Jean C, Dubé, Marie-Pierre, Samuel, Michelle, Morel, Olivier, Lim, Pascal, Bertrand, Olivier F, Kouz, Simon, Guertin, Marie-Claude, L’Allier, Philippe L, Roubille, Francois |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7700755/ https://www.ncbi.nlm.nih.gov/pubmed/32860034 http://dx.doi.org/10.1093/eurheartj/ehaa659 |
Ejemplares similares
-
Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)
por: Samuel, Michelle, et al.
Publicado: (2020) -
Pharmacogenomics of the Efficacy and Safety of Colchicine in COLCOT
por: Dubé, Marie-Pierre, et al.
Publicado: (2021) -
Predictive risk factors for hospitalization and response to colchicine in patients with COVID-19
por: Tardif, Jean-Claude, et al.
Publicado: (2022) -
Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome:
the dal-GenE trial( )
por: Tardif, Jean Claude, et al.
Publicado: (2022) -
Colchicine reduces atherosclerotic plaque vulnerability in rabbits
por: Roubille, François, et al.
Publicado: (2021)